Evaxion Biotech A/S ADR EVAX 深 沪
等待开盘 09-19 09:30:00 美东时间
3.02
+0.095
+3.25%
华盛通- 最 高3.15
- 今 开3.00
- 成交量 4.31万股
- 最 低 2.94
- 昨 收 2.925
- 总市值 1907.61万
- 52周最高 15.6975
- 市盈率 静 --
- 换手率 0.00%
- 52周最低 1.20
- 委 比 -80.22%
- 总股本 631.66万
- 历史最高 1252.00
- 量 比 1.27
- 振 幅 7.18%
- 历史最低 2.94
- 每 手 1
- 风险率 4.30%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Evaxion Announces Conference Participation for H2 2025
Evaxion Biotech ( ($EVAX) ) has shared an announcement. On August 27, 2025, Eva...
08-27 20:46
Evaxion to present at several conferences during the second half of 2025
Evaxion A/S will present data and updates at numerous scientific and investor conferences across the US, Europe, and Asia in the second half of 2025. The company plans to engage with stakeholders, including potential partners, and share insights on its AI-Immunology platform and personalized cancer vaccine EVX-01. Key events include the ESMO Congress in October, where two-year clinical data for EVX-01 will be presented. Evaxion aims to strengthen...
08-27 12:00
Evaxion shares are trading lower after the company reported a year-over-year decrease in Q2 sales results.
Evaxion shares are trading lower after the company reported a year-over-year de...
08-14 23:52
Earnings Scheduled For August 14, 2025
Companies Reporting Before The Bell • Sunlands Technology (NYSE:STG) is likely ...
08-14 16:32
Insights Ahead: Evaxion Biotech's Quarterly Earnings
Evaxion Biotech (NASDAQ:EVAX) will release its quarterly earnings report on Thu...
08-14 02:02
Evaxion to present two-year clinical efficacy data from phase 2 trial with AI-designed personalized cancer vaccine EVX-01 at the ESMO Congress 2025
Evaxion A/S will present two-year clinical data from its phase 2 trial for EVX-01, a personalized cancer vaccine for advanced melanoma, at the 2025 ESMO Congress in Berlin. EVX-01, developed using Evaxion's AI-Immunology™ platform, has shown promising results in early trials, including a 69% Overall Response Rate and tumor reduction in 15 out of 16 patients. The presentation will highlight long-term efficacy and immune response data. The phase 2 ...
07-25 13:00
12 Health Care Stocks Moving In Monday's Pre-Market Session
Gainers Sonnet BioTherapeutics (NASDAQ:SONN) shares rose 239.4% to $17.55 dur...
07-14 20:08
Evaxion Finalizes Agreement With EIB To Convert Debt Into Equity; EIB To Convert €3.5M Of €7M Loan To Evaxion Into Equity Via Purchase Of Ordinary Evaxion Warrants At $4.87
Evaxion and the European Investment Bank (EIB) have finalized a debt settlement agreement of €3.5 million out of Evaxion's €7 million loan with EIB, to be used for EIB to purchase €3.5 million worth of ordinary Evaxion
07-11 20:07
Evaxion announces changes to Executive Management to optimize the value of proprietary AI-Immunology™ platform and portfolio
Christian Kanstrup has stepped down as CEO of Evaxion A/S. Dr. Birgitte Rønø, the Chief Scientific Officer, has been appointed interim CEO, and the search for a new permanent CEO has begun. Additionally, Thomas Schmidt has been named permanent Chief Financial Officer. The company aims to optimize the value of its AI-Immunology™ platform under these leadership changes.
07-01 12:30
12 Health Care Stocks Moving In Wednesday's After-Market Session
Gainers Adial Pharmaceuticals (NASDAQ:ADIL) stock moved upwards by 19.6% to $0...
06-26 05:06
